share_log

Shattuck Labs | 10-Q: Q2 2024 Earnings Report

Shattuck Labs | 10-Q: Q2 2024 Earnings Report

Shattuck Labs | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/02 04:24

Moomoo AI 已提取核心訊息

Shattuck Labs reported Q2 2024 financial results with collaboration revenue increasing 704% to $1.6 million, driven by the Ono Pharmaceutical agreement and ImmunoGen partnership. Net loss was $21.6 million compared to $21.3 million in Q2 2023. Research and development expenses rose 5.7% to $19.2 million due to increased manufacturing costs for clinical trials.The company highlighted progress with its lead candidate SL-172154, sharing positive Phase 1B data in higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) at EHA 2024. Clinical responses showed improved rates compared to standard therapy, with manageable safety profile. Shattuck initiated additional randomized controlled cohorts in both HR-MDS and TP53 mutant AML to further evaluate efficacy.As of June 30, 2024, Shattuck had $105.3 million in cash and investments, which is expected to fund operations into 2026. The company continues to advance its ARC platform technology while exploring potential applications in autoimmune and inflammatory diseases through the Ono collaboration, which could provide up to $217.5 million in milestone payments plus royalties.
Shattuck Labs reported Q2 2024 financial results with collaboration revenue increasing 704% to $1.6 million, driven by the Ono Pharmaceutical agreement and ImmunoGen partnership. Net loss was $21.6 million compared to $21.3 million in Q2 2023. Research and development expenses rose 5.7% to $19.2 million due to increased manufacturing costs for clinical trials.The company highlighted progress with its lead candidate SL-172154, sharing positive Phase 1B data in higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) at EHA 2024. Clinical responses showed improved rates compared to standard therapy, with manageable safety profile. Shattuck initiated additional randomized controlled cohorts in both HR-MDS and TP53 mutant AML to further evaluate efficacy.As of June 30, 2024, Shattuck had $105.3 million in cash and investments, which is expected to fund operations into 2026. The company continues to advance its ARC platform technology while exploring potential applications in autoimmune and inflammatory diseases through the Ono collaboration, which could provide up to $217.5 million in milestone payments plus royalties.
Shattuck Labs 發佈了2024年第二季度財務報告，其中合作營業收入比去年增加了704%，達到了160萬美元，這得益於與Ono藥品的協議和與ImmunoGen的合作。淨虧損爲2160萬美元，而2023年第二季度爲2130萬美元。由於臨牀試驗的製造成本增加，研發支出上漲了5.7%，達到1920萬美元。該公司強調了其主要候選藥物SL-172154的進展，在2024年EHA會議上分享了在高風險骨髓增生異常綜合徵（HR-MDS）和TP53突變的急性髓性白血病（AML）方面的積極第10億階段數據。臨牀反應顯示與標準療法相比，改善了反應率，並且安全性可控。Shattuck啓動了額外的隨機對照隊列...展開全部
Shattuck Labs 發佈了2024年第二季度財務報告，其中合作營業收入比去年增加了704%，達到了160萬美元，這得益於與Ono藥品的協議和與ImmunoGen的合作。淨虧損爲2160萬美元，而2023年第二季度爲2130萬美元。由於臨牀試驗的製造成本增加，研發支出上漲了5.7%，達到1920萬美元。該公司強調了其主要候選藥物SL-172154的進展，在2024年EHA會議上分享了在高風險骨髓增生異常綜合徵（HR-MDS）和TP53突變的急性髓性白血病（AML）方面的積極第10億階段數據。臨牀反應顯示與標準療法相比，改善了反應率，並且安全性可控。Shattuck啓動了額外的隨機對照隊列，以進一步評估在HR-MDS和TP53突變的AML中的療效。截至2024年6月30日，Shattuck擁有現金和投資10530萬美元，預計可以支持其運營直到2026年。該公司繼續推進其ARC平台科技，同時通過與Ono的合作探索在自身免疫和炎症疾病中的潛在應用，可能提供高達21750萬美元的里程碑付款加上版稅。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間